Literature DB >> 8934229

Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity.

S Ager1, B H Nilson, F J Morling, K W Peng, F L Cosset, S J Russell.   

Abstract

Five different single-chain antibody fragments (scFv) against human cell-surface antigens were displayed on murine ecotropic retroviral vectors by fusing them to the Moloney SU envelope glycoprotein. The spacing between the scFv and the SU glycoprotein was varied by fusing the scFv to residue +7 or to residue +1 of Moloney SU and by inserting linker sequences of different lengths between the domains. All of the chimeric envelopes were efficiently incorporated into vector particles and could bind to human cells through their displayed antibody fragments, but did not infect them. The spacing between the scFvs and the SU glycoproteins had no significant effect on the efficiency of envelope expression or viral incorporation and did not affect the binding properties of the chimeric envelopes, nor did it influence the efficiency of targeted gene delivery to human cells by scFv-displaying vectors. However, on murine fibroblasts the infectivity of vectors incorporating the chimeric envelopes was strongly influenced by the length of the interdomain spacer. The titers were very low when the single-chain antibodies were fused through a tripeptide linker to SU residue +7 and were greatly enhanced (up to 10(5)-fold) when they were fused to SU residue +1 through a heptapeptide linker. These results point to the importance of steric interactions between the domains of chimeric envelope glycoproteins and may have implications for retroviral vector design for human gene therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8934229     DOI: 10.1089/hum.1996.7.17-2157

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  11 in total

1.  Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types.

Authors:  A L Boerger; S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Identification of the block in targeted retroviral-mediated gene transfer.

Authors:  Y Zhao; L Zhu; S Lee; L Li; E Chang; N W Soong; D Douer; W F Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

3.  Two point mutations produce infectious retrovirus bearing a green fluorescent protein-SU fusion protein.

Authors:  K Kizhatil; A Gromley; L M Albritton
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Antibody-directed targeting of retroviral vectors via cell surface antigens.

Authors:  K Morizono; G Bristol; Y M Xie ; S K Kung; I S Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor.

Authors:  S Snitkovsky; T M Niederman; B S Carter; R C Mulligan; J A Young
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Receptor co-operation in retrovirus entry: recruitment of an auxiliary entry mechanism after retargeted binding.

Authors:  S Valsesia-Wittmann; F J Morling; T Hatziioannou; S J Russell; F L Cosset
Journal:  EMBO J       Date:  1997-03-17       Impact factor: 11.598

7.  Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells.

Authors:  Changming Yu; Gennett M Pike; Tommy A Rinkoski; Cristina Correia; Scott H Kaufmann; Mark J Federspiel
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

8.  Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein.

Authors:  S Snitkovsky; J A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

9.  Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule.

Authors:  Haiguang Yang; Kye-Il Joo; Leslie Ziegler; Pin Wang
Journal:  Pharm Res       Date:  2009-03-04       Impact factor: 4.200

Review 10.  Viral vectors for gene transfer: a review of their use in the treatment of human diseases.

Authors:  W Walther; U Stein
Journal:  Drugs       Date:  2000-08       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.